fatti
acid
major
sourc
fuel
bodi
play
import
role
cell
signal
free
fatti
acid
ffa
nonesterifi
fatti
acid
releas
hydrolysi
triglycerid
triglycerid
molecul
compos
three
fatti
acid
molecul
bound
glycerol
within
adipos
tissu
lipoprotein
lipas
circul
blood
proteinbound
serv
energi
sourc
tissu
chronic
elev
ffa
level
observ
obes
peopl
diabet
patient
associ
insulin
resist
sudden
death
middleag
men
without
known
ischem
heart
diseas
acut
ffa
level
often
increas
critic
ill
may
contribut
organ
dysfunct
critic
ill
character
hypercatabol
state
chang
contribut
endogen
protein
fat
carbohydr
sourc
oxid
fuel
lipolysi
acceler
high
catecholamin
stress
hormon
milieu
lead
increas
releas
ffa
adipocyt
thu
increas
ffa
level
insulin
resist
critic
ill
impair
use
ffa
energi
thu
contribut
increas
ffa
level
heparin
given
critic
ill
may
also
increas
ffa
level
activ
lipoprotein
lipas
ffa
may
toxic
effect
increas
reactiv
oxygen
speci
lead
cell
death
necrosi
depress
immun
cell
function
addit
ffa
potenti
insulin
resist
impair
glucos
metabol
inhibit
glucos
oxid
stimul
protein
kinas
c
acut
set
elev
ffa
level
associ
develop
acut
lung
injuri
atrisk
patient
sepsi
trauma
pancreat
onpump
coronari
arteri
bypass
graft
ffa
level
critic
ill
patient
modul
shortterm
calor
restrict
permiss
underfeed
normal
serum
ffa
level
increas
fast
exercis
fatti
meal
ffa
level
goe
postprandi
due
antilipolyt
effect
insulin
releas
carbohydr
intak
hand
calor
restrict
weight
loss
lead
lower
ffa
level
attenu
ffasinduc
hepat
insulin
resist
obes
healthi
patient
howev
effect
calor
restrict
serum
ffa
level
investig
critic
ill
patient
aim
studi
evalu
clinic
nutrit
correl
high
ffa
level
critic
ill
patient
associ
outcom
studi
effect
shortterm
calor
restrict
permiss
underfeed
ffa
level
critic
ill
preplan
substudi
permit
permiss
underfeed
vs
target
enter
feed
adult
critic
ill
trial
critic
ill
patient
random
permiss
underfeed
calcul
calor
requir
standard
feed
day
maintain
similar
protein
intak
group
trial
found
differ
primari
endpoint
mortal
substudi
separ
fund
king
abdulaziz
citi
scienc
technolog
kacst
riyadh
saudi
arabia
grant
numberat
kacst
enrol
consecut
patient
permit
trial
king
abdulaziz
medic
citi
riyadh
saudi
arabia
septemb
septemb
expect
stay
day
intens
care
unit
judg
primari
team
separ
inform
consent
obtain
particip
substudi
studi
approv
institut
board
review
ministri
nation
guard
health
affair
riyadh
saudi
arabia
blood
collect
time
enrol
baselin
studi
day
within
h
icu
admiss
day
serum
prepar
blood
sampl
centrifug
c
g
min
divid
aliquot
aliquot
store
immedi
design
freez
area
c
analyz
sampl
size
complet
sampl
analyz
blindli
sampl
code
broken
measur
ffa
perform
bioscientia
refer
laboratori
germani
use
invitro
enzymat
calorimetr
assay
wakonefahr
reagent
wakochem
neuss
germani
method
ffa
coexist
coenzym
coa
atp
disodium
salt
convert
acylcoa
adenosin
monophosph
amp
pyrophosphor
acid
action
acylcoa
synthetas
ac
acylcoa
oxid
yield
hydrogen
peroxid
h
action
acylcoa
oxidas
presenc
peroxidas
h
yield
bluepurpl
pigment
quantit
oxid
condens
anilin
meha
ffa
level
obtain
measur
absorb
blue
purpl
color
wavelength
nm
nm
normal
fast
serum
ffa
level
mmoll
femal
mmoll
male
howev
ffa
level
critic
ill
poorli
studi
current
studi
patient
ffa
mmoll
femal
mmoll
male
consid
high
ffa
level
otherwis
ffa
level
consid
normal
baselin
data
includ
demograph
acut
physiolog
chronic
health
evalu
score
apach
ii
presenc
sepsi
upon
admiss
sequenti
organ
failur
assess
sofa
score
ratio
partial
pressur
arteri
oxygen
fraction
inspir
oxygen
pao
fio
glasgow
coma
scale
variou
laboratori
result
baselin
blood
glucos
hemoglobin
intern
normal
ratio
inr
platelet
bilirubin
creatinin
creactiv
protein
albumin
prealbumin
transferrin
urinari
urea
nitrogen
excret
nitrogen
balanc
intervent
period
last
day
collect
daili
nutrit
data
feed
formula
calori
enter
feed
propofol
intraven
dextros
parenter
nutrit
insulin
dose
hyperglycemia
manag
daili
blood
glucos
use
certain
medic
aspirin
betablock
statin
note
daili
carbohydr
fat
protein
calori
enter
parenter
sourc
calcul
total
fattocarbohydr
ratio
divid
fat
calori
carbohydr
calori
outcom
evalu
studi
allcaus
mortal
outcom
includ
hospit
icu
mortal
incid
renal
replac
therapi
icuassoci
infect
icu
hospit
length
stay
lo
mechan
ventil
durat
addit
icufre
day
renal
replac
therapyfre
day
ventilatorfre
day
also
calcul
report
categor
variabl
frequenc
percentag
continu
variabl
median
quartil
compar
categor
variabl
use
chisquar
fisher
exact
test
continu
variabl
use
mannwhitney
u
test
examin
pearson
correl
among
follow
baselin
variabl
ffa
level
age
bodi
mass
index
total
cholesterol
highdens
lipoprotein
hdl
cholesterol
lowdens
lipoprotein
ldl
cholesterol
nonhdl
cholesterol
triglycerid
glucos
hemoglobin
addit
multivari
logist
regress
analysi
perform
assess
predictor
high
ffa
level
enter
model
priori
decid
baselin
variabl
clinic
interest
andor
signific
associ
high
ffa
level
univari
analysi
p
includ
age
gender
bodi
mass
index
bmi
apach
ii
diabet
triglycerid
ldl
cholesterol
hdl
cholesterol
medic
admiss
vs
nonmed
admiss
random
permiss
vs
standard
feed
also
carri
linear
mix
model
test
whether
ffa
level
affect
time
permiss
underfeed
compar
standard
feed
carri
logist
linear
regress
model
examin
associ
ffa
level
outcom
adjust
age
gender
bmi
apach
ii
diabet
triglycerid
ldl
cholesterol
hdl
cholesterol
nonhdl
cholesterol
medic
admiss
vs
nonmed
admiss
twotail
p
valu
consid
statist
signific
result
express
adjust
odd
ratio
aor
paramet
estim
confid
interv
ci
statist
analys
perform
use
sa
version
sa
institut
cari
nc
usa
patient
includ
studi
figur
high
ffa
level
median
mmoll
normal
ffa
level
mmoll
patient
high
ffa
level
significantli
older
like
femal
diabet
higher
creatinin
nonhdl
ldl
cholesterol
level
lower
pao
fio
ratio
compar
patient
normal
ffa
tabl
signific
correl
ffa
level
total
cholesterol
r
p
nonhdl
cholesterol
r
p
hdl
cholesterol
r
p
ldl
cholesterol
r
p
age
r
p
tabl
tabl
show
nutrit
data
studi
period
trial
cointervent
total
daili
calor
intak
ffa
level
p
baselin
blood
glucos
similar
two
group
howev
studi
period
glucos
level
significantli
higher
patient
high
ffa
level
compar
patient
normal
ffa
level
mmoll
compar
mmoll
p
higher
use
insulin
unit
per
day
compar
unit
per
day
p
addit
patient
high
ffa
level
receiv
diseasespecif
formula
renal
replac
therapi
aspirin
statin
icu
stay
multivari
logist
regress
analysi
independ
predictor
high
ffa
level
diabet
aor
ci
p
baselin
cholesterol
aor
ci
p
figur
panel
show
serial
level
ffa
patient
high
ffa
normal
ffa
figur
panel
b
show
ffa
level
patient
receiv
permiss
underfeed
standard
feed
ffa
level
differ
two
feed
strategi
multivari
logist
regress
analysi
independ
predictor
high
ffa
level
diabet
aor
ci
p
baselin
cholesterol
aor
ci
p
figur
panel
show
serial
level
ffa
patient
high
ffa
normal
ffa
figur
panel
b
show
ffa
level
patient
receiv
permiss
underfeed
standard
feed
ffa
level
differ
two
feed
strategi
patient
receiv
permiss
underfeed
standard
feed
panel
b
p
valu
betweengroup
differ
betweengroup
differ
time
provid
use
mix
linear
model
signific
differ
crude
mortal
patient
high
normal
ffa
level
tabl
incid
renal
replac
therapi
frequent
patient
high
ffa
level
compar
p
multipl
variabl
analys
adjust
age
gender
bmi
apach
ii
diabet
triglycerid
ldl
cholesterol
hdl
cholesterol
nonhdl
cholesterol
medic
admiss
vs
nonmed
admiss
show
signific
associ
high
ffa
level
mortal
aor
ci
p
studi
outcom
tabl
p
valu
betweengroup
differ
betweengroup
differ
time
provid
use
mix
linear
model
signific
differ
crude
mortal
patient
high
normal
ffa
level
tabl
incid
renal
replac
therapi
frequent
patient
high
ffa
level
compar
p
multipl
variabl
analys
adjust
age
gender
bmi
apach
ii
diabet
triglycerid
ldl
cholesterol
hdl
cholesterol
nonhdl
cholesterol
medic
admiss
vs
nonmed
admiss
show
signific
associ
high
ffa
level
mortal
aor
ci
p
studi
outcom
tabl
studi
evalu
serum
ffa
level
critic
ill
patient
found
ffa
level
elev
baselin
patient
associ
featur
metabol
syndrom
ffa
level
affect
permiss
underfeed
versu
standard
feed
high
ffa
level
appear
larg
reflect
underli
metabol
condit
patient
rather
critic
ill
studi
provid
character
critic
ill
patient
high
ffa
level
found
high
ffa
level
correl
highli
lipid
profil
paramet
total
hdl
ldl
cholesterol
triglycerid
age
compar
normal
ffa
level
patient
high
ffa
level
baselin
significantli
older
like
diabet
higher
blood
glucos
creatinin
nonhdl
ldl
cholesterol
concentr
hypoxemia
reflect
lower
ratio
despit
lack
differ
apach
ii
score
sofa
score
vasopressor
demand
icu
stay
patient
high
ffa
level
increas
demand
insulin
diseasespecif
nutrit
therapi
rrt
aspirin
statin
differ
suggest
associ
high
ffa
level
metabol
syndrom
differ
bmi
two
group
howev
bmi
known
limit
predict
obes
differ
carri
multivari
analys
account
confound
effect
variabl
clinic
outcom
analys
show
high
ffa
level
associ
independ
clinic
outcom
interestingli
patient
high
ffa
level
less
urinari
nitrogen
excret
less
neg
nitrogen
balanc
may
relat
lower
muscl
mass
older
popul
frequent
insulin
therapi
normal
ffa
elev
fast
exercis
level
drop
postprandi
carbohydraterich
meal
ffa
level
elev
obes
diabet
acut
critic
ill
lipolysi
increas
serum
ffa
level
increas
studi
demonstr
onethird
critic
ill
patient
high
ffa
level
patient
diabet
found
baselin
cholesterol
level
diabet
independ
risk
factor
high
ffa
level
multivari
logist
regress
analysi
effect
propofol
ffa
level
uncertain
experi
dog
undergo
gener
anesthesia
high
concentr
propofol
mcgkgmin
associ
increas
ffa
level
although
studi
human
undergo
gener
anesthesia
cardiopulmonari
bypass
show
propofol
mcgkgmin
compar
midazolam
alter
serum
ffa
level
studi
categor
patient
high
low
ffa
level
base
baselin
serum
specimen
dose
propofol
preced
enrol
collect
studi
design
specif
address
effect
propofol
ffa
level
nevertheless
dose
propofol
use
icu
stay
averag
much
lower
use
studi
therefor
effect
propofol
ffa
level
cohort
like
small
slightli
lower
dose
propofol
given
patient
highffa
level
like
relat
older
suscept
sedat
therefor
patient
would
normal
receiv
smaller
dose
propofol
addit
fuel
sourc
ffa
multipl
physiolog
effect
ffa
associ
insulin
resist
impair
glucos
metabol
inhibit
glucos
oxid
stimul
protein
kinas
c
may
also
stimul
autophagi
pancreat
beta
cell
studi
patient
high
ffa
level
higher
blood
glucos
requir
insulin
therapi
icu
stay
even
though
baselin
blood
glucos
level
similar
patient
high
normal
ffa
suggest
associ
ffa
insulin
resist
icu
patient
ffa
may
also
affect
cours
acut
critic
ill
ffa
found
exacerb
hyperglycemiainduc
tolllik
receptor
express
activ
monocyt
cell
increas
superoxid
releas
enhanc
nuclear
activ
induc
releas
proinflammatori
factor
diabet
whether
ffa
affect
inflamm
critic
ill
patient
less
clear
porcin
endotoxemia
model
infus
lipid
two
differ
concentr
associ
differ
plasma
tumor
necrosi
leucocyt
anim
low
high
ffa
suggest
ffa
play
signific
proinflammatori
mediat
effect
howev
ffa
implic
pathogenesi
acut
respiratori
distress
syndrom
identifi
prognost
factor
syndrom
lipopolysaccharideinduc
acut
lung
injuri
model
increas
free
oleic
acid
observ
bronchoalveolar
lavag
fluid
mice
h
lipopolysaccharid
applic
ffa
oleic
acid
demonstr
elev
patient
ard
acut
respiratori
distress
syndrom
patient
atrisk
ard
patient
sepsi
demonstr
sixfold
increas
plasma
oleic
acid
level
compar
healthi
volunt
addit
ffa
elev
blood
patient
sepsi
increas
risk
ard
exact
mechan
ffasassoci
lung
injuri
unclear
howev
ffa
shown
increas
permeabl
impair
transepitheli
activ
sodium
transport
mechan
lung
could
thu
promot
alveolar
edema
format
prevent
edema
resolut
studi
almost
patient
mechan
ventil
baselin
hypoxemia
signific
patient
high
ffa
compar
patient
normal
ffa
median
ratio
vs
p
find
may
line
associ
ffa
lung
injuri
whether
ffa
toxic
kidney
unclear
anim
studi
ffa
led
sever
tubulointerstiti
damag
ffa
metabolit
implic
renal
cell
injuri
develop
chronic
kidney
patient
metabol
syndrom
studi
patient
high
ffa
higher
rate
new
renal
replac
therapi
although
associ
becam
signific
multivari
analysi
find
suggest
observ
crude
associ
may
relat
confound
put
patient
higher
risk
acut
kidney
injuri
exampl
patient
high
ffa
level
like
diabet
higher
baselin
creatinin
compar
patient
normal
ffa
level
weight
loss
lead
lower
ffa
level
long
run
attenu
ffasinduc
hepat
insulin
resist
obes
healthi
patient
howev
effect
shortterm
calor
restrict
differ
one
studi
subject
fed
two
period
day
hypoand
eucalor
diet
macronutri
composit
random
order
day
fast
ffa
significantli
increas
hypocalor
diet
compar
eucalor
diet
whether
macronutri
composit
affect
ffa
investig
anim
model
studi
found
energyrestrict
highfat
versu
lowfat
diet
result
differ
ffa
level
current
studi
serial
level
ffa
differ
time
patient
receiv
permiss
underfeed
standard
feed
studi
result
interpret
take
consider
strength
limit
strength
includ
data
came
random
control
trial
serial
measur
ffa
obtain
limit
includ
sampl
size
make
studi
underpow
detect
mortal
differ
measur
total
ffa
individu
level
ffa
addit
studi
includ
patient
expect
durat
icu
stay
day
thu
result
may
generaliz
patient
shorter
stay
conclus
found
serum
ffa
level
elev
almost
onethird
critic
ill
patient
high
ffa
level
associ
featur
metabol
syndrom
affect
shortterm
moder
calor
restrict
supplementari
materi
follow
avail
onlin
http
tabl
pearson
correl
among
baselin
free
fatti
acid
ffa
level
relat
measur
lipid
metabol
figur
flow
diagram
patient
enrol
substudi
free
fatti
acid
ffa
level
